Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells.
about
Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer.The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.Monocyte-derived dendritic cells from cirrhotic patients retain similar capacity for maturation/activation and antigen presentation as those from healthy subjects.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.Persistent Antigen and Prolonged AKT-mTORC1 Activation Underlie Memory CD8 T Cell Impairment in the Absence of CD4 T Cells.Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.Role of dendritic cells in the regulation of antitumor immunityTrial Watch: Immunostimulatory monoclonal antibodies for oncological indications.PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell-Driven Antitumor Immunity.Yeast-containing feed additive alters gene expression profiles associated with innate immunity in whole blood of a rodent model.
P2860
Q30252919-CC9CF416-18FC-4C20-AF87-DE0442A88060Q30317628-DC034B08-8948-4555-B486-4253BB5C43CCQ33776925-F62CA480-C200-41B0-8FE6-3DBB41F26AD5Q33931006-FEAB3DB2-B35E-41B3-AF4C-64431F10044DQ35514419-A0289592-1780-421B-92E2-1507C7D5745DQ35833912-76702B53-FD89-43A4-B313-273131600D82Q35931373-E383CF88-B8C7-4EDA-9BB4-1D3A4FD3A3BAQ35938555-4B760DDC-E938-4080-B3AE-679F3D15716AQ36845842-27FDB4DE-A82E-48B3-AB97-842E711114ADQ47325431-B251E1B6-516B-4B75-8742-3EA9CA0FB5E4Q52668712-58FB540B-99DB-44E0-A065-FE02B0A4F056Q55026032-A79E39A7-5E57-4CBC-8477-3CA805150DD5
P2860
Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Differential requirement for C ...... f tumor-tolerized CD8 T cells.
@ast
Differential requirement for C ...... f tumor-tolerized CD8 T cells.
@en
type
label
Differential requirement for C ...... f tumor-tolerized CD8 T cells.
@ast
Differential requirement for C ...... f tumor-tolerized CD8 T cells.
@en
prefLabel
Differential requirement for C ...... f tumor-tolerized CD8 T cells.
@ast
Differential requirement for C ...... f tumor-tolerized CD8 T cells.
@en
P2093
P2860
P356
P1476
Differential requirement for C ...... f tumor-tolerized CD8 T cells.
@en
P2093
Eileen M Higham
Jianzhu Chen
K Dane Wittrup
Mike Stein Barnkob
S Peter Bak
P2860
P304
P356
10.4049/JIMMUNOL.1201271
P407
P577
2012-07-13T00:00:00Z